Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both-Reference-Cited by-同舟云学术

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

Published:2016-02-08 Issue:5 Volume:30 Page:1018-1024
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Koschmieder S,Mughal T I,Hasselbalch H C,Barosi G,Valent P,Kiladjian J-J,Jeryczynski G,Gisslinger H,Jutzi J S,Pahl H L,Hehlmann R,Maria Vannucchi A,Cervantes F,Silver R T,Barbui T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201612.pdf

Reference70 articles.

1. Milosevic JD, Kralovics R . Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol 2013; 97: 183–197.

2. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.

3. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.

4. Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients. Blood 2015; 127: 333–342.

5. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I et al. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. Blood 2015; 127: 325–332.

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving landscape of polycythemia vera therapies;Expert Opinion on Pharmacotherapy;2024-07-23

2. Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis;Leukemia;2024-07-18

3. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis;Blood;2024-06-06

4. miR‐146a^−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype;American Journal of Hematology;2024-04-22

5. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms—a Danish longitudinal study;Blood Cancer Journal;2024-02-09